ReviewBipolar disorders2025
Early use of long-acting injectable antipsychotics in bipolar disorder type I: An expert consensus.
Review in Bipolar disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Understanding Antipsychotic Polypharmacy in Bipolar Disorder: The Role of Long-Acting Injectable Antipsychotics in a Naturalistic Inpatient Setting.The Psychiatric quarterly · 2026Article
- Risperidone long-acting in-situ microimplant following a brief oral risperidone lead-in in the acute inpatient management of manic episodes with psychotic symptoms in non-adherent patients with schizoaffective disorder: a retrospective, uncontrolled real-world study.Annals of general psychiatry · 2026Article
- Views on an antipsychotic regimen administered once every 2 months: a qualitative interview study of people living with bipolar I disorder, caregivers, and prescribers in the USA and Canada.International journal of bipolar disorders · 2026Article
- The effect of early initiation of aripiprazole once-monthly 400 mg on health care resource utilization and health care costs in patients diagnosed with bipolar I disorder: Real-world evidence from US claims data.Journal of managed care & specialty pharmacy · 2026Article
- Understanding long-acting injectables in the context of treatment planning for schizophrenia: crafting a strategy.CNS spectrums · 2025Review
- The Promise of Long-acting Injectable Antipsychotics for the Treatment of Bipolar I Disorder: The Role of Manic Predominance.Actas espanolas de psiquiatria · 2025Article
- Two-Injection Start Regimen of Long-Acting Injectable Aripiprazole: Retrospective Data From a Tertiary Care Hospital in Turkey.Alpha psychiatry · 2025Article
- Long-Acting Injectables: A Strategy to Mitigate Nonadherence in Bipolar Disorder.Bipolar disorders · 2025Article
- Early use of long-acting injectable antipsychotics in bipolar disorder type I: An expert consensus.Bipolar disorders · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionLong-acting injectable antipsychotics (LAIs) are not routinely offered to patients living with bipolar disorder type I (BP-I), despite widespread evidence that supports their benefits over oral antipsychotics, particularly in early disease.
methodsA round-table meeting of psychiatrists convened to discuss barriers and opportunities and provide consensus recommendations around the early use of LAIs for BP-I.
resultsLAIs are rarely prescribed to treat BP-I unless a patient has severe symptoms, sub-optimal adherence to oral antipsychotics, or has experienced multiple relapses. Beyond country-specific accessibility issues (e.g., healthcare infrastructure and availability/approval status), primary barriers to the effective use of LAIs were identified as attitudinal and knowledge/experience-based. Direct discussions between healthcare providers and patients about treatment preferences may not occur due to a preconceived notion that patients prefer oral antipsychotics. Moreover, as LAIs have historically been limited to the treatment of schizophrenia and the most severe cases of BP-I, healthcare providers might be unaware of the benefits LAIs provide in the overall management of BP-I. Improved treatment adherence associated with LAIs compared to oral antipsychotics may support improved outcomes for patients (e.g., reduced relapse and hospitalization). Involvement of all stakeholders (healthcare providers, patients, and their supporters) participating in the patient journey is critical in early and shared decision-making processes. Clinical and database studies could potentially bridge knowledge gaps to facilitate acceptance of LAIs.
conclusionThis review discusses the benefits of LAIs in the management of BP-I and identifies barriers to use, while providing expert consensus recommendations for potential solutions to support informed treatment decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.